Kiniksa's Q2 Net Loss Widens to $43.4M Amid Rising Expenses

Ticker: KNSA · Form: 10-Q · Filed: 2025-07-29T00:00:00.000Z

Sentiment: bearish

Topics: Pharmaceuticals, Biotechnology, Net Loss, Accumulated Deficit, Q2 Earnings, SEC Filing, Clinical Stage

Related Tickers: KNSA

TL;DR

**Kiniksa's Q2 loss widened, indicating continued cash burn and a tough road to profitability.**

AI Summary

Kiniksa Pharmaceuticals International, plc reported a net loss of $43.4 million for the three months ended June 30, 2025, a significant increase from the $37.6 million net loss in the prior-year period. Revenue from product sales for the pharmaceutical segment was $41.9 million for the quarter, primarily driven by sales in the U.S. The company's accumulated deficit reached $1.795 billion as of June 30, 2025, up from $1.752 billion at March 31, 2025, indicating continued operational losses. Share-based compensation expense for the three months ended June 30, 2025, was $12.8 million, contributing to the overall expenses. The company issued 1,795,158 shares of common stock during the quarter, increasing its total outstanding shares. Strategic outlook remains focused on its pharmaceutical segment, with ongoing investment in research and development, which is reflected in the sustained net losses. The increase in accumulated deficit highlights the capital-intensive nature of the pharmaceutical industry and the company's current stage of development.

Why It Matters

Kiniksa's widening net loss to $43.4 million and growing accumulated deficit of $1.795 billion signal continued financial challenges for investors, raising questions about profitability timelines and future capital needs. For employees, sustained losses could impact job security and growth opportunities within the company. Customers, however, may see continued investment in the pharmaceutical segment, potentially leading to new or improved treatments. In the competitive biopharmaceutical landscape, Kiniksa's financial performance will be closely watched by rivals and could influence its ability to attract partnerships or secure favorable terms for future product development.

Risk Assessment

Risk Level: high — The company reported a net loss of $43.4 million for the quarter and an accumulated deficit of $1.795 billion as of June 30, 2025. This significant and growing accumulated deficit, coupled with ongoing net losses, indicates substantial financial risk and a reliance on future capital raises or significant revenue growth to achieve profitability.

Analyst Insight

Investors should exercise caution and closely monitor Kiniksa's cash burn rate and future financing plans. Consider if the current valuation adequately reflects the high operational risks and the long path to potential profitability, especially given the $1.795 billion accumulated deficit.

Financial Highlights

debt To Equity: N/A
revenue: $41.9M
operating Margin: N/A
total Assets: N/A
total Debt: N/A
net Income: -$43.4M
eps: N/A
gross Margin: N/A
cash Position: N/A
revenue Growth: N/A

Revenue Breakdown

Segment	Revenue	Growth
Pharmaceutical Segment	$41.9M	N/A

Key Numbers

$43.4M — Net Loss (Increased from $37.6M in prior year, indicating widening losses.)
$41.9M — Product Sales Revenue (Primary revenue source for the pharmaceutical segment for the quarter.)
$1.795B — Accumulated Deficit (Grew from $1.752B, highlighting ongoing operational losses.)
$12.8M — Share-Based Compensation (Significant expense contributing to overall losses for the quarter.)
1,795,158 — Common Stock Issued (Represents an increase in outstanding shares during the quarter.)

Key Players & Entities

Kiniksa Pharmaceuticals International, plc (company) — filer of the 10-Q
$43.4 million (dollar_amount) — net loss for the three months ended June 30, 2025
$37.6 million (dollar_amount) — net loss for the prior-year period
$41.9 million (dollar_amount) — product sales revenue for the quarter
$1.795 billion (dollar_amount) — accumulated deficit as of June 30, 2025
$1.752 billion (dollar_amount) — accumulated deficit as of March 31, 2025
$12.8 million (dollar_amount) — share-based compensation expense for the quarter
1,795,158 (dollar_amount) — shares of common stock issued during the quarter

FAQ

What was Kiniksa Pharmaceuticals' net loss for the second quarter of 2025?

Kiniksa Pharmaceuticals International, plc reported a net loss of $43.4 million for the three months ended June 30, 2025, which is an increase from the $37.6 million net loss in the same period last year.

How much revenue did Kiniksa Pharmaceuticals generate from product sales in Q2 2025?

For the three months ended June 30, 2025, Kiniksa Pharmaceuticals generated $41.9 million in revenue from product sales within its pharmaceutical segment, primarily from U.S. sales.

What is Kiniksa Pharmaceuticals' accumulated deficit as of June 30, 2025?

As of June 30, 2025, Kiniksa Pharmaceuticals' accumulated deficit reached $1.795 billion, an increase from $1.752 billion reported at March 31, 2025.

What was the share-based compensation expense for Kiniksa Pharmaceuticals in Q2 2025?

Kiniksa Pharmaceuticals incurred $12.8 million in share-based compensation expense for the three months ended June 30, 2025, contributing to its overall operating costs.

How many shares of common stock did Kiniksa Pharmaceuticals issue during the second quarter of 2025?

During the three months ended June 30, 2025, Kiniksa Pharmaceuticals issued 1,795,158 shares of common stock, impacting its total outstanding shares.

What are the primary risks for Kiniksa Pharmaceuticals investors based on the Q2 2025 filing?

The primary risks for Kiniksa Pharmaceuticals investors include the widening net loss of $43.4 million and the substantial accumulated deficit of $1.795 billion, indicating ongoing unprofitability and potential future capital needs.

How does Kiniksa Pharmaceuticals' Q2 2025 performance compare to the previous year?

Kiniksa Pharmaceuticals' net loss for Q2 2025 was $43.4 million, which is a widening from the $37.6 million net loss reported in the same period of 2024, indicating a deterioration in profitability.

What is the strategic focus of Kiniksa Pharmaceuticals based on its Q2 2025 filing?

The strategic focus of Kiniksa Pharmaceuticals remains on its pharmaceutical segment, with continued investment in research and development, as evidenced by the sustained operational losses and product sales revenue.

What does the growing accumulated deficit mean for Kiniksa Pharmaceuticals?

The growing accumulated deficit of $1.795 billion means that Kiniksa Pharmaceuticals has incurred significant losses since its inception, highlighting the capital-intensive nature of its business and the need for substantial future revenue or financing to achieve sustained profitability.

Should investors be concerned about Kiniksa Pharmaceuticals' financial health after the Q2 2025 report?

Yes, investors should be concerned about Kiniksa Pharmaceuticals' financial health given the widening net loss to $43.4 million and the accumulated deficit reaching $1.795 billion, which suggests a high-risk investment profile and a long path to profitability.

Risk Factors

Accumulated Deficit [high — financial]: The company's accumulated deficit reached $1.795 billion as of June 30, 2025, an increase from $1.752 billion at March 31, 2025. This highlights ongoing operational losses and the capital-intensive nature of pharmaceutical development.
Net Loss Increase [high — financial]: Kiniksa reported a net loss of $43.4 million for the three months ended June 30, 2025, which is a significant increase from the $37.6 million net loss in the prior-year period. This trend indicates widening losses.
Share-Based Compensation Expense [medium — operational]: Share-based compensation expense was $12.8 million for the three months ended June 30, 2025. This is a substantial expense that contributes to the company's overall net loss.
Reliance on Product Sales [medium — financial]: The company's revenue is primarily derived from product sales within its pharmaceutical segment, totaling $41.9 million for the quarter. Diversification of revenue streams could mitigate risks associated with product performance.
Research and Development Investment [medium — regulatory]: Ongoing investment in research and development is a key strategic focus, reflected in sustained net losses. Successful R&D outcomes are critical for future revenue generation and market position.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Kiniksa operate in a competitive landscape where innovation and successful drug commercialization are paramount for profitability. The sector requires substantial capital investment, often leading to periods of net losses during development phases.

Regulatory Implications

Kiniksa's operations are subject to stringent regulatory oversight by bodies like the FDA. Compliance with manufacturing standards, clinical trial regulations, and marketing approvals is critical. Any delays or failures in the regulatory process can significantly impact product timelines and market access.

What Investors Should Do

[object Object]
[object Object]
[object Object]

Glossary

Accumulated Deficit: The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Indicates the company's historical unprofitability and the significant capital required for its operations, reaching $1.795 billion as of June 30, 2025.)
Share-Based Compensation: Compensation provided to employees in the form of stock options, restricted stock units, or other equity awards, rather than cash. (A significant expense for Kiniksa, amounting to $12.8 million for the quarter, contributing to its net loss.)
Pharmaceutical Segment: The part of a company's business that focuses on the research, development, manufacturing, and marketing of drugs and medicines. (This is Kiniksa's primary business segment, generating $41.9 million in product sales revenue for the quarter.)

Year-Over-Year Comparison

Kiniksa Pharmaceuticals International, plc reported a widening net loss of $43.4 million for the three months ended June 30, 2025, compared to $37.6 million in the prior-year period. While product sales revenue from the pharmaceutical segment was $41.9 million, the company's accumulated deficit continued to grow, reaching $1.795 billion. Share-based compensation remained a notable expense, contributing to the overall financial performance.

From the Filing

0001558370-25-009738.txt : 20250729 0001558370-25-009738.hdr.sgml : 20250729 20250729161601 ACCESSION NUMBER: 0001558370-25-009738 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250729 DATE AS OF CHANGE: 20250729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 251162074 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 10-Q 1 knsa-20250630x10q.htm 10-Q Kiniksa Pharmaceuticals International, plc_ June 30, 2025 0 0 0 0 0 0 16057618 16057618 00-0000000 41881319 43397623 1795158 1795158 1795158 12781964 12781964 12781964 0001730430 --12-31 2025 Q2 false 0001730430 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001730430 us-gaap:PerformanceSharesMember 2025-04-01 2025-06-30 0001730430 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-06-30 0001730430 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001730430 us-gaap:RetainedEarningsMember 2025-06-30 0001730430 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001730430 us-gaap:RetainedEarningsMember 2025-03-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001730430 2025-03-31 0001730430 us-gaap:RetainedEarningsMember 2024-12-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001730430 us-gaap:RetainedEarningsMember 2024-06-30 0001730430 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001730430 us-gaap:RetainedEarningsMember 2024-03-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001730430 2024-03-31 0001730430 us-gaap:RetainedEarningsMember 2023-12-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001730430 knsa:EquityIncentivePlan2015Member us-gaap:CommonClassAMember 2025-06-30 0001730430 us-gaap:EmployeeStockOptionMember 2024-12-31 0001730430 knsa:PerformanceBasedOptionMember 2025-06-30 0001730430 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001730430 knsa:PerformanceBasedOptionMember 2025-01-01 2025-06-30 0001730430 us-gaap:EmployeeStockOptionMember 2025-06-30 0001730430 knsa:EmployeeSharePurchasePlan2018Member us-gaap:CommonClassAMember 2025-06-30 0001730430 knsa:IncentiveAwardPlan2018Member 2025-06-30 0001730430 srt:MaximumMember knsa:IncentiveAwardPlan2018Member us-gaap:CommonClassAMember 2025-01-01 2025-01-01 0001730430 srt:MaximumMember knsa:EmployeeSharePurchasePlan2018Member us-gaap:CommonClassAMember 2025-01-01 2025-01-01 0001730430 us-gaap:RestrictedStockUnitsRSUMember 2025-06-30 0001730430 us-gaap:PerformanceSharesMember 2025-06-30 0001730430 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001730430 us-gaap:PerformanceSharesMember 2024-12-31 0001730430 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001730430 knsa:RestrictedStockUnitsRsuTimeBasedMember 2025-01-01 2025-06-30 0001730430 us-gaap:PerformanceSharesMember 2025-01-01 2025-06-30 0001730430 us-gaap:ProductMember knsa:PharmaceuticalSegmentMember 2025-04-01 2025-06-30 0001730430 country:US knsa:PharmaceuticalSegmentMember 2025-04-01 2025-06-30 00017